Introduction
The Hemophilia Joint Health Score (HJHS) is a vital, validated outcome tool designed to assess joint health in individuals with hemophilia. First introduced in 2011 by Brian M. Feldman, Sharon M. Funk, Britt-Marie Bergstrom, and a team of international experts, the HJHS has since become an indispensable tool in the fields of hematology and musculoskeletal assessment. Consequently, its primary validation study has amassed over 350 citations, underscoring its significant impact and widespread adoption within the hemophilia research and clinical community.
This article serves as an expert guide, meticulously detailing the HJHS’s key features, clinical applications, and research value. Ultimately, it provides clinicians and researchers with the necessary insights for effectively incorporating this powerful instrument into their practice and studies.
Key Features of the Hemophilia Joint Health Score (HJHS)
Purpose and Use
The primary purpose of the Hemophilia Joint Health Score (HJHS) is to provide a validated outcome tool for assessing joint health in people with hemophilia. Specifically, it evaluates joint-related impairments through a standardized clinical examination of six index joints (elbows, knees, and ankles) combined with a global gait assessment. Consequently, this structured approach enables clinicians and researchers to detect early arthropathy, quantify joint damage, and monitor changes in musculoskeletal status over time, thereby facilitating timely intervention and informed treatment decisions.
Target Population
The HJHS is validated for individuals with hemophilia aged 4 years and older. Its target population includes:
Children (Under 13 years)Adolescents (13–17 years)Young Adults (18–24 years)Middle-Aged Adults (25–44 years)Older Adults (45–64 years)Seniors (65+ years)The HJHS is specifically designed for people with hemophilia to assess joint health and detect early arthropathy across the lifespan, from early childhood through adulthood.
Structure
The Hemophilia Joint Health Score (HJHS) is a clinician-administered instrument designed to evaluate joint health through a structured physical examination. It consists of 8 items scored per joint for six index joints (elbows, knees, and ankles), plus a separate global gait score, resulting in a comprehensive assessment of musculoskeletal status.
The joint-specific items evaluate the following domains:
Swelling: Presence and severity of joint swellingDuration of Swelling: How long swelling has been presentMuscle Atrophy: Loss of muscle mass around the jointCrepitus on Motion: Grinding or cracking sound or feeling during movementFlexion Loss: Decrease in joint bending rangeExtension Loss: Decrease in joint straightening rangeJoint Pain: Pain during movement or at restStrength: Muscle strength around the jointBeyond the joint-specific assessment, the instrument includes a global gait and function score. This component observes and scores the person's walking pattern (gait), running, jumping, and other general physical activities to identify any limitations or abnormalities.
The HJHS utilizes a clinician-rated ordinal scoring system, with each item scored on a defined scale. The instrument is available in multiple versions, including HJHS v1.0 (2006) and HJHS v2.0 (2011) , with the latter representing the current validated version.
Scoring Method
The scoring method for the Hemophilia Joint Health Score (HJHS) utilizes a structured, additive approach based on a clinician-rated ordinal scoring system. Each of the eight joint-specific items is scored per joint across six index joints (elbows, knees, and ankles), with response options and score ranges varying by the parameter assessed:
Swelling: Rated on a 4-point scale (0–3)Duration of Swelling: Rated on a 2-point scale (0–1)Muscle Atrophy: Rated on a 3-point scale (0–2)Crepitus on Motion: Rated on a 3-point scale (0–2)Flexion Loss: Rated on a 4-point scale (0–3)Extension Loss: Rated on a 4-point scale (0–3)Joint Pain: Rated on a 3-point scale (0–2)Strength: Rated on a 5-point scale (0–4)For each of the six joints, the eight item scores are summed, yielding a maximum joint score of 20 per joint. The scores from all six joints are summing with the global gait score (rated 0–4 on a 5-point scale) resulting in a total HJHS score ranging from 0 to 124.
Higher total scores indicate worse joint health and greater joint damage. A score of zero represents optimal joint health with no detectable impairment. Any score above zero indicates the presence of some degree of joint abnormality.
A change of 4 points or more in the total HJHS score over a period of 6 to 12 months is considered clinically meaningful and often warrants a review of the treatment plan. Importantly, the HJHS does not have universal diagnostic cut-off score; rather, the target is zero, and any increase from baseline signals deterioration in joint health.
Administration Format
The HJHS is a clinician-administered assessment tool, typically taking 5 to 10 minutes to complete. It is administered via:
In-person interview and physical examinationNotably, administration requires advanced training and certification to ensure reliability and consistency in scoring.
Applications of the Hemophilia Joint Health Score (HJHS)
The Hemophilia Joint Health Score (HJHS) is a versatile tool with several key applications in clinical practice and research:
Screening: It helps identify early joint arthropathy and detect joint impairment in individuals with hemophilia before significant damage occurs.Monitoring: It allows clinicians to reliably track joint health progression or improvement over time, particularly during routine follow-up visits and prophylaxis management.Treatment Planning: Scores can inform clinical decisions regarding prophylaxis regimens, physical therapy interventions, and treatment adjustments based on the presence and severity of joint impairment.Research: It serves as a reliable and validated primary or secondary outcome measure in clinical trials and observational studies investigating hemophilia treatment efficacy, joint health outcomes, and musculoskeletal interventions.Languages and availability
Due to its global adoption, the Hemophilia Joint Health Score (HJHS) has been translated and validated in numerous languages, including:
ArabicEnglishMandarin ChineseSpanishFrenchGermanAnd other (Portuguese, Japanese, Turkish, and Korean)The HJHS is free for non-commercial clinical and academic research use, making it highly accessible for routine practice and studies. It is published under an open access license, allowing for widespread use without licensing fees. However, formal training and certification are required for proper administration to ensure reliable and consistent scoring.
Reliability and Validity
The Hemophilia Joint Health Score (HJHS) is recognized as a highly reliable and valid instrument for assessing joint health in individuals with hemophilia. Its psychometric soundness is well-documented, with a Cronbach's alpha of 0.86, indicating excellent internal consistency.
Key validation resources include:
The Original Validation Study linkLimitations and Considerations
Despite its strengths, the Hemophilia Joint Health Score (HJHS) has several important limitations that should be considered when implementing the tool in practice or research:
Cultural Bias: The interpretation of certain items may vary across cultures, potentially affecting the consistency and comparability of scores in diverse populations.Rater/Examiner Dependency: As a clinician-reported outcome measure, scores are dependent on the examiner's skills, experience, and adherence to standardized protocols, which can introduce variability between different raters.Time-Consuming: The HJHS requires a comprehensive physical examination of six index joints plus gait assessment, making it more time-consuming compared to simpler patient-reported outcome measures or imaging-based tools.Requires Specialized Training: Administration demands advanced training and certification to ensure reliability and consistency, which may limit its use in settings where trained examiners are not available.Researchers and clinicians should account for these limitations when interpreting results and consider supplementing the HJHS with complementary tools such as patient-reported outcome measures or imaging assessments to obtain a more holistic view of the patient's joint health status.
Other Versions And Related Questionnaires
Researchers and clinicians should be aware of other versions of the questionnaire:
HJHS Version 1.0 (2006): The original version of the Hemophilia Joint Health Score, which established the foundational framework for assessing joint health in individuals with hemophilia.HJHS Version 2.0 (2011): The updated and refined version of the tool, which is the current standardized version used in clinical practice and research.Additionally, the HJHS can be used alongside complementary assessment tools for comprehensive hemophilia care, such as:
Functional Independence Score in Hemophilia (FISH)Hemophilia Activities List (HAL)Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)Additional Resources
The Original Validation Study linkHaemophilia joint health score (HJHS) usage, patterns and outcome data in patients in Australia linkA Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions linkDeveloping a new scoring scheme for the Hemophilia Joint Health Score 2.1 linkFor inquiries, contact Brian M. Feldman at feldman@sickkids.caFrequently Asked Questions (FAQ)
1. Who can use the HJHS?
Healthcare professionals, including physical therapists, physiatrists, and hematologists, use the HJHS to assess joint health in individuals with hemophilia aged four years and older.
2. How long does it take to administer the HJHS?
The administration time is approximately 5 to 10 minutes, making it a practical tool for routine clinical assessments and research studies.
3. How is the HJHS administered?
The HJHS is administered via an in-person interview and physical examination by a trained clinician. It requires a hands-on assessment of six index joints and observation of global gait.
4. Is there any cost to using the HJHS?
The HJHS is free to use under an open-access license. This allows researchers and clinicians to utilize the tool without any associated fees.
A Word from ResRef about Hemophilia Joint Health Score (HJHS)
The Hemophilia Joint Health Score (HJHS) represents the clinical gold standard for monitoring joint health in hemophilia. Its strength lies in a comprehensive, standardized evaluation of both specific joint impairments and global physical function. By enabling the early detection of arthropathy, it serves as a critical tool for guiding prophylaxis and treatment decisions. The requirement for trained clinical administration ensures reliability and consistency in scores over time. When combined with patient-reported outcome measures, it provides a holistic view of the patient's status. Thus, the HJHS is indispensable for optimizing long-term musculoskeletal outcomes in hemophilia care.
References
Feldman, B. M., Funk, S. M., Bergstrom, B.-M., Zourikian, N., Hilliard, P., van der Net, J., Engelbert, R., Petrini, P., van den Berg, H. M., Manco-Johnson, M. J., Rivard, G. E., Abad, A., & Blanchette, V. S. (2011). Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score. Arthritis Care & Research, 63(2), 223–230. linkMcPherson, S., McLeod, S., Curnow, J., & Dunkley, S. (2024). Haemophilia joint health score (HJHS) usage, patterns and outcome data in patients in Australia. Haemophilia, 30(3), 712–720. linkSun, J., Hilliard, P. E., Feldman, B. M., Zourikian, N., Chen, L., Blanchette, V. S., & Manco-Johnson, M. J. (2025). A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions. PharmacoEconomics, 43(3), 295–306. linkRibeiro, T., Abad, A., & Feldman, B. M. (2019). Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1. Research and Practice in Thrombosis and Haemostasis, 3(3), 405–411. link